Lilly’s Oral GLP-1 Orforglipron Shows Significant Weight Loss in Phase 3 ATTAIN-1 Trial

Eli Lilly and Company

Eli Lilly and Company announced that its investigational oral GLP-1 receptor agonist, orforglipron, delivered an average weight loss of 27.3 lbs in the Phase 3 ATTAIN-1 trial. The once-daily pill demonstrated a safety profile consistent with existing injectable GLP-1 therapies and also showed improvements in cardiovascular risk factors.

Amgen’s MariTide Shows Promising Results in Phase 2 Obesity Study with Monthly Dosing

amgen

Amgen presented Phase 2 data showing that its investigational obesity therapy, maritide, administered monthly, led to significant weight loss in adults with obesity or overweight. The treatment was generally well tolerated, supporting further clinical development.

Novo Nordisk Announces Positive Results for Higher-Dose Wegovy®, Showing Significant Weight Loss in Adults with Obesity

novo nordisk

Novo Nordisk has announced compelling results from its phase 3b STEP UP clinical trial, demonstrating that a higher 7.2 mg dose of its weight-loss medication, Wegovy® (semaglutide), led to a significant average weight loss of 21% in adults with obesity.